《中国心力衰竭诊断和治疗指南 2024》药物更新透视  

Pharmacologic Therapy Updates of 2024 Guidelines for the Diagnosis and Treatment of Heart Failure in China

作　　者：吴娟[1,2] 龙萍 曾露 王璐[1] 贡雪芃 魏安华 WU Juan;LONG Ping;ZENG Lu;WANG Lu;GONG Xuepeng;WEI Anhua(Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Pharmacy,Taikang Tongji(Wuhan)Hospital,Wuhan 430050,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,武汉430030 [2]泰康同济(武汉)医院药学部,武汉430050

出　　处：《医药导报》2024年第11期1718-1722,共5页Herald of Medicine

摘　　要：心力衰竭是各种心脏疾病的严重表现或晚期阶段,病死率和再住院率居高不下。《中国心力衰竭诊断和治疗指南2024》在2018年版基础上,结合新的循证医学证据和中国国情,对心力衰竭分类、诊断、预防、治疗、合并症和管理等内容均作了全面系统的阐述和推荐。该文对该指南治疗药物部分的更新进行综述。Heart failure is a severe manifestation or advanced stage of various heart diseases,with high mortality and readmission rates.The 2024 guidelines for the diagnosis and treatment of heart failure,which are on the 2018 guidelines,combined with new evidence and China's national conditions,provide a comprehensive and systematic description and recommendation on the classification,diagnosis,prevention,treatment,comorbidity,and management of heart failure.This article reviewed the update of the therapeutic drugs section.

关 键 词：心力衰竭 药物治疗 指南 

分 类 号：R972[医药卫生—药品] R541[医药卫生—药学]